Which drugs may be selected by the provider for initial treatment for a patient who is diagnosed with relapsing-remitting MS? (Select all that apply. One. some, or all)

A. Mitoxantrone (Novantrone) is a cytotoxic drug used for more advanced or worsening multiple sclerosis, such as secondary progressive, progressive-relapsing, or rapidly worsening relapsing-remitting MS. It is not typically used for initial treatment due to its cardiotoxicity and risk of leukemia. B. Interferon beta-1a (Avonex) is a first-line disease-modifying therapy (DMT) for relapsing-remitting MS (RRMS). It reduces the frequency and severity of relapses and slows the progression of physical disability. Administered intramuscularly, it modulates immune response and decreases inflammation in the CNS. C. Methotrexate (Rheumatrex) is an immunosuppressive drug primarily used for rheumatoid arthritis, psoriasis, and certain cancers. It is not a standard first-line treatment for RRMS. D. Teriflunomide (Aubagio) is an oral disease-modifying therapy approved for initial treatment of RRMS. It reduces the frequency of relapses by inhibiting the proliferation of activated lymphocytes. Its oral administration makes it convenient for long-term therapy. E. Dimethyl fumarate (Tecfidera) is another oral first-line DMT for RRMS. It has anti-inflammatory and cytoprotective effects that reduce relapses and slow disability progression.